$7.7M grant OK'd for Framingham project Oct 30, 2009
The $7 million announced yesterday will go to the construction of an enhanced wastewater collection system to account for expansions at Genzyme Corp., which is building a new bio-manufacturing facility on New York Avenue ... She also said the town has repeatedly benefited over the years from Genzyme's local presence ... In a statement yesterday, Town Manager Julian Suso said the project "will facilitate the strategic expansion of Genzyme Corp., allowing Genzyme to considerably enhance their... (Framingham TAB, MA)
ARM Holdings, BP, GlaxoSmithKline, RBS, Yell: U.K., Irish Equity Preview Oct 27, 2009
(GSK LN): The U.K.s largest drugmaker and Genmab A/S won U.S. approval of a new leukemia treatment for patients who dont get better on drugs such as Genzyme Corp.s Campath. The shares fell 6. (Bloomberg -- UK)
Cash infusion could push Framingham water, sewer project forward Oct 27, 2009
9 million - thanks to a 2008 life sciences bill - to improve infrastructure that would allow for Genzyme Corp. to expand its presence in Framingham. The town has received $5. (Framingham TAB, MA)
US sees late sell-off as bank optimism fades Oct 22, 2009
In the regular session, biotechnology company Genzyme Corp was the Nasdaq's top drag after it posted lower-than-expected quarterly earnings and cut its 2009 outlook. The stock fell 6. (Sydney Morning Herald -- Business)
Earnings roundup Oct 22, 2009
Plant closure stifles Genzyme ... Genzyme, the world s largest maker of drugs for rare genetic disorders, said in June it would ration two drugs, Cerezyme and Fabrazyme, after the company shut its Allston Landing plant in Boston to decontaminate after detecting a virus called Vesivirus 2117 ... Most of Genzyme s medicines treat hereditary disorders caused by lack of enzymes needed for critical bodily functions. (Boston Globe)
Genzyme begins Phase 3 clinical trial Oct 21, 2009
Genzyme currently markets Cerezyme, an injectable treatment for Gaucher disease, an enzyme deficiency in which fatty substances accumulate in the spleen, liver, lungs, bone marrow, and sometimes the brain. Genzyme has been rationing Cerezyme because of a virus found in the production equipment of its Allston plant ... In a statement yesterday, Genzyme senior vice president Dr. Geoff McDonough said: We remain very enthusiastic about this potential new therapy for Gaucher disease, which could... (Boston Globe)
Mepha Pharma will receive first round bids on 23 October Oct 21, 2009
He did not comment on specific possible specialty pharma bidders, but said Genzyme did not make sense. However, there is a US-specialty company equivalent to Shire that could bid for Mepha, he said. (FT.com -- Markets)
Drug Shortages and Public Health Oct 15, 2009
The viral contamination of a Genzyme manufacturing plant in Massachusetts, detected in June 2009, caused an unexpected shortage of imiglucerase (Cerezyme), for. . (New England Journal of Medicine)
Genzyme must further study drug Oct 7, 2009
Based on findings from a limited trial, Genzyme sought approval to market the drug to patients with the most common form of blood and bone marrow cancer in adults, the Cambridge, Mass ... Genzyme plans to request a meeting with the FDA to discuss which studies will satisfy its requirements to use the drug for untreated adults. (Boston Globe)
Twitter used to help sell Web company Oct 5, 2009
Sometimes, the idea creates a big hometown company, like Fidelity or Genzyme, and sometimes it creates a company that eventually gets acquired by an outsider. And a few more things I like about Revolutionary ideas start here : The slogan embraces both academia and commerce; it works equally well for Boston or Massachusetts or all of New England; and it wasn t cooked up by a committee or consortium. (Boston Globe)
The bio governor hails possibility of life sciences industry Oct 2, 2009
officials from Genzyme, Merck, Wadsworth Medical Technologies, Eutropics, Organogenesis and the University of Massachusetts were on hand. Those relationships are cited as a strength by proponents of boosting the industry and a flaw by those who say life sciences companies shouldn t be getting favored treatment by the state. (Burlington Union, MA)
Science survey ranks top biopharma employers Oct 2, 2009
Boehringer Ingelheim of Ingelheim, Germany, comes in a close second, with Genzyme of Cambridge, Massachusetts, completing the top three. This year's survey identified 17 other top pharmaceutical and biotechnology companies, making up a top 20 of biopharma employers. (EurekAlert! -- Business News)
Iron Mountain director uses stock to his advantage Raytheon's Swanson chooses cash option Bruker cashes out Laukiens Oct 2, 2009
Carpenter, Robert J $2,574,191 GENZYME CORP. GENZ ... Termeer, Henri A $544,849 GENZYME CORP. GENZ ... Cooney, Charles L $180,570 GENZYME CORP. GENZ. (Boston Business Journal, MA)
Roslindale's Rogerson Communities celebrates A Matter of Balance graduations Sep 30, 2009
With grant funding from Tufts Health Plan Foundation and Genzyme Corporation, Rogerson has brought this program to six Greater Boston affordable elder housing facilities and plans to expand the program throughout its network of facilities and programs that provide support services to the elder community. Visit Rogerson. (West Roxbury Transcript, MA)
Genzyme drug study gets good results Sep 25, 2009
Genzyme did not specify how much time the combination extended a person s life without the disease progressing. Campath is already approved as a leukemia treatment; the company is seeking Food and Drug Administration approval to sell it as a combination therapy, as well. (Boston Globe)
Commuter shuttle bus proposed to link downtown Framingham, business districts Sep 25, 2009
9 corridor, to businesses like Genzyme, Bose and Staples. She suggested a subscriber-based bus service that would run in accordance with the train schedule. (Framingham TAB, MA)
President Clinton Hosts Special Session on Northern Ireland; Announces New Commitments Focused on Harnessing Innovation for Development Sep 24, 2009
Genzyme Corporation and its partners commit to raise awareness for and support passage of legislation recently introduced in the U.S. Congress for a partial tax credit that provides financial incentive for companies to invest in neglected tropical disease (NTD) research and development. Genzyme will also continue to support new work under existing collaborations for NTDs. (PR Newswire)
Genzyme expects shortages of two drugs to end by 2010 Sep 24, 2009
Genzyme said it has successfully restarted its Allston Landing plant in Boston, which was closed by viral contamination in June, but initial supplies of Fabrazyme will be lower than anticipated ... Genzyme started rationing Cerezyme, used for Gaucher disease, and Fabrazyme, for Fabry disease, after discovering the virus ... Fabrazyme was Genzyme s third-biggest drug, generating $494 million, or about 11 percent of sales. (Boston Globe)
Inverness deal, Biogen Idec offer reflect acquisition fever among biotech firms Sep 22, 2009
Meanwhile, some analysts have speculated that Genzyme, also based in Cambridge, could be a takeover target if it fails to get under control recent production problems at its Allston plant, where scientists discovered a virus last spring. The problems caused Genzyme s share price to tumble over the summer, but it has since rebounded. (Boston Globe)
China News 2009.09.18 Sep 21, 2009
Genzyme Corp., the world's third largest biotechnology firm by revenue, has started construction of a 100 million U.S. dollar research and development center in Beijing. The company aims to cash in on the country's growing need for healthcare while also tapping into its talent pool. (Xinhuanet, China)
Genzyme struggles to recover from virus Sep 21, 2009
Genzyme struggles to rebound from virus setback - The Boston Globe ... CAMBRIDGE - Genzyme Corp. s chief executive, Henri A. Termeer, was at his summer home in Maine on June 13 when he got a phone call confirming what he already feared: A virus had infected a bioreactor at his company s Allston Landing plant, forcing a halt to the production of two expensive drugs that treat rare genetic disorders ... Genzyme had told patients, doctors, investors, regulators, Allston community leaders, and the... (Boston Globe)
Rail Tale: Tracks key downtown Framingham redevelopment Sep 18, 2009
The Prudential Center in Boston and a Genzyme complex near the Allston/Cambridge line sit on former railyards, she said. Steve Cecil, one of the town's consultants, mentioned taking advantage of Farm Pond. (Framingham TAB, MA)
Genzyme Factory Woes May Give Shire $50 Million Windfall on Drug Shortage Sep 11, 2009
Sept. 11 (Bloomberg) -- , the U.K. maker of the hyperactivity drug Adderall, may reap a $50 million windfall in 2010 after its treatment for the rare genetic disorder was rushed to the market a year earlier than planned because of a manufacturing disruption at Genzyme Corp.. Genzymes setback also hands Shire the chance to garner $139 million in revenue in 2011, according to Citigroup Inc., which says Shires velaglucerase alfa may grab 15 percent of the $1 ... The majority of Gaucher... (Bloomberg)
Local Boys & Girls Clubs ramp up fund-raising efforts Sep 10, 2009
The organization found one recently, winning support from biotechnology company Genzyme, which operates a facility in Framingham. Waltham is restrategizing, too. (Boston Globe)
Targeted Genetics sells assets for $7M Sep 10, 2009
Targeted Genetics sells some assets for $7M, stock soars 50 percent - Puget Sound Business Journal (Seattle). for free extra services. (Puget Sound Business Journal, WA)
Biotech firm pioneers knee repair procedure Sep 4, 2009
O Donnell says his company hopes to capitalize on the technology that biotech giants like Cambridge-based Genzyme Corp. have already introduced. We see the opportunity to build on their success with a better solution, he adds. (Woburn Advocate, MA)
Letter: Back to School backpack drive a success Sep 3, 2009
Major donors included Cushman and Wakefield, Bay State Federal Savings Charitable Foundation, American Twine, and Genzyme. There were also many individuals who contributed. (Cambridge Chronicle, MA)
NY judge gives ex-Monster exec 2 years in prison Sep 3, 2009
Zacks Analyst Blog Highlights: Bristol-Myers Squibb, Amgen, Genzyme, Aetna and United Health ... Stocks recently featured in the blog include: Bristol-Myers Squibb ( 00004000 NYSE: BMY ), Amgen (Nasdaq: AMGN ), Genzyme (Nasdaq: GENZ ), Aetna (NYSE: AET ) and United Health (NYSE: UNH ). (Fresno Bee -- Business)
Dreadful Stocks to Avoid Sep 2, 2009
In fact, one reason Genzyme (Nasdaq: GENZ) has been so successful is that it has devoted so much to top-notch research and development. Nevertheless, there is a downside to research. (MSNBC -- Business)
FDA Panel Wants More Information On Leukemia Drug Sep 2, 2009
WASHINGTON (September 1, 2009)--A panel of cancer experts has issued a negative review of a leukemia drug from Genzyme, saying more data is needed to establish its safety for older patients ... -based Genzyme did not conduct the necessary study to prove its injectable drug Clolar is safe and effective ... The FDA asked Genzyme to conduct a randomized study, which compares patients taking the drug to those taking alternative treatments. (KWTX.com, TX)
FDA seeks new trial of Genzyme drug Sep 2, 2009
WASHINGTON - A panel of cancer experts has issued a negative review of a leukemia drug from Genzyme, saying more data is needed to establish its safety and efficacy for older patients ... -based Genzyme should be required to conduct a larger, comparison study to prove its drug is safe and effective ... Genzyme is seeking approval for adults with leukemia who are older than 60, but are not healthy enough to undergo chemotherapy. (Boston Globe)
Analyst Picks and Pans: Fannie Mae, Freddie Mac, Genzyme Sep 1, 2009
Shares of Genzyme Corp. fell in premarket trade on Aug. 31 after Robert W. Baird analyst Christopher J. Raymond said more potential manufacturing delays could cut into sales of Cerezyme, a drug that treats Gaucher disease, an enzyme disorder that can result in liver and neurological problems ... In June, Genzyme temporarily shut down its production facility in the Boston neighborhood of Allston to clean up viral contamination that had been slowing down the process for making supplies of Cerezyme... (BusinessWeek)
Businesses uneasy without Kennedy Sep 1, 2009
WHAT WILL BE MISSED Genzyme CEO Henri A. Termeer noted Kennedy s support of innovation. By Globe Staff / September 1, 2009. (Boston Globe)
Inspectors find major flaw at Genzyme plant Sep 1, 2009
In June, workers were decontaminating Genzyme s plant ... Bo Piela, a spokesman for Genzyme, said the company will not have to cease production of drugs made at the plant ... Genzyme, which makes drugs to treat rare and chronic diseases, was forced to temporarily halt production at the plant in June due to a virus contamination. (Boston Globe)
Cleaned-up plant’s new boss pulls out all the stops Aug 31, 2009
Sandra E. Poole must help rebuild Genzyme s drug inventories and polish its reputation ... Sandra E. Poole may have landed the toughest job in biotechnology: running Genzyme Corp. s Allston Landing plant ... The Cambridge-based biotech giant has been struggling to overcome production problems at the plant that caused a summer shutdown and the temporary rationing of a pair of Genzyme s key enzyme replacement drugs, Cerezyme and Fabrazyme. (Boston Globe)
FDA questions Genzyme drug study Aug 30, 2009
Henri Termeer is CEO of Genzyme, which looked at 112 patients in its Clolar study ... FDA reviewers complained Genzyme s study did not compare patients taking Clolar with those taking a sham treatment, a common practice to gauge a drug s effect. (Boston Globe)
Adamas signs with US Navy to make flu treatment Aug 29, 2009
Search Type Choose a search type from the items below. Tue Aug 18, 3:14 pm ET. (Yahoo News -- Pharmaceutical Industry News)
FDA criticizes Genzyme study of leukemia drug Clolar Aug 29, 2009
FDA criticizes Genzyme study of leukemia drug ... Just days before a key meeting to consider Genzyme Corp. s application for a new leukemia drug to treat older patients, the Food and Drug Administration released a briefing document criticizing the Cambridge biotechnology company s clinical study of the drug, called Clolar ... Genzyme said the drug deserves to be approved to treat adult acute myeloid leukemia in people who aren t healthy enough to undergo chemotherapy, citing results of its study... (Boston Globe)
Cerezyme option to get fast-track review at FDA Aug 26, 2009
If approved, the Protalix drug, called prGCD, would compete with Genzyme Corp. s Cerezyme, the only approved treatment ... -based Genzyme ran into production problems earlier this year ... Genzyme halted production of Cerezyme and another drug, Fabrazyme, at its Allston Landing plant for a month in June after discovering a virus in a bioreactor used to make the products. (Boston Globe)
Let the race begin Aug 21, 2009
So regulators will permit doctors to prescribe two other yet-to-be approved treatments for patients who would otherwise be stuck rationing Cerezyme until Genzyme can prove it has beaten the virus found in a bioreactor two months ago ... Genzyme became one of the state s largest biotech companies thanks to an unusual strategy that depends on a stable of high-priced drugs to treat rare genetic disorders ... Stock analysts who follow Genzyme estimate the drug generates a gross profit margin of... (Boston Globe)
2d Cerezyme rival available in trials Aug 18, 2009
For the second time in two weeks, federal regulators have moved to counter the ongoing supply shortage of Cerezyme, Genzyme Corp. s treatment for Gaucher disease, by letting doctors prescribe a rival drug before it has won approval for commercial use ... Genzyme halted production of Cerezyme and another drug, Fabrazyme, at its Allston Landing plant for a month in June after discovering a virus in a bioreactor used to make the products ... Meantime, Genzyme has been rationing Cerezyme, reducing... (Boston Globe)
Genzyme guidance falls amid plant delays Aug 14, 2009
Genzyme also said sales of Myozyme will fall to between $330 million and $340 million down from an earlier prediction of $370 million-to-$380 million ... In June, Genzyme said it would temporarily halt production at the manufacturing facility after the company detected a virus that impairs cell growth in one of the site s six bioreactors ... For the three months ended June 30, Genzyme booked $1. (Boston Business Journal, MA)
Law firm recruits shareholders for Genzyme suit Aug 14, 2009
Rahn s suit alleges that Genzyme failed to promptly disclose two warning letters the company received from the FDA regarding maintenance procedures at the Allston plant ... Genzyme officials, in an interview last week, said that the maintenance and manufacturing issues raised by the FDA were related to equipment used in the later stages of biologics production and therefore could not have been responsible for the introduction of a virus that hit a bioreactor at the Allston plant ... Genzyme... (Boston Business Journal, MA)
Genzyme closes drug plant due to virus Aug 14, 2009
Genzyme Corp. has temporarily halted production at its Allston, Mass ... Investors turned on the company s stock shortly after the news was confirmed Tuesday, pushing Genzyme s (Nasdaq: GENZ) stock down roughly 7 percent to $51 ... Genzyme is currently working to sanitize the facility and is collaborating with regulatory agencies as it works to resume production. (Boston Business Journal, MA)
Genzyme dumps unfinished drug, says more charge-offs may be in order Aug 13, 2009
The development is another setback for both Genzyme s finances and for patients who take the drug Cerezyme. Genzyme said the move will worsen the supply shortfalls for its Gaucher s disease treatment ... As a result of dumping the unfinished batches of Cerezyme, Genzyme will have to take an $8. (Boston Business Journal, MA)
U.S. Commerce secretary to make stop at Cambridge's Genzyme Aug 13, 2009
In the afternoon, Locke will tour the Genzyme Corporation s headquarters in Cambridge, Mass ... Genzyme s headquarters is registered with the U.S. Green Building Council under the Leadership in Energy and Environmental Design (LEED) 2 ... From rooftop gardens that reduce rainwater run-off, to a sophisticated system that uses waste steam from a nearby power plant to cool the facility, the Genzyme building was designed in an environmentally friendly way. (Cambridge Chronicle, MA)
FDA seeks contingency details from Genzyme Aug 13, 2009
FDA inspectors will examine Genzyme s cleanup campaign at its Allston plant, where a virus was discovered in June ... The company is the only supplier of the drugs Fabrazyme and Myozyme, and the request from the FDA raises the possibility that regulators could revoke Genzyme s so-called orphan drug status, which gives it seven years of exclusivity for drugs to treat conditions affecting 200,000 or fewer people ... But some industry analysts said such a move was unlikely, noting that Genzyme s... (Boston Globe)
Genzyme dumps unfinished inventory over virus concerns Aug 12, 2009
Genzyme dumps unfinished drug, says more charge-offs may be in order - Boston Business Journal ... Genzyme dumps unfinished drug, says more charge-offs may be in order ... The development is another setback for both Genzyme s finances and for patients who take the drug Cerezyme. (Boston Business Journal, MA)
Some companies left behind in bull's dust Aug 12, 2009
Biotech company Genzyme is one of the larger firms to miss out on the rally, falling 10% to $49. 36. (USA Today -- Money)
Genzyme to discard drug’s raw materials Aug 11, 2009
Genzyme to discard drug s raw materials - The Boston Globe ... Genzyme to discard drug s raw materials ... Even with yesterday s disclosure, Genzyme said, it remains on schedule to begin shipping new lots of Cerezyme in November and December. (Boston Globe)
Stock questions? Ask Matt Aug 11, 2009
Rising tide has lifted most boats, but these stocks sank - USATODAY.com. Rising tide has lifted most boats, but these stocks sank. (USA Today -- Money)
Genzyme rival gets positive test results Aug 4, 2009
British drug maker Shire PLC stepped up the pressure on Cambridge biotechnology company yesterday, reporting positive test results for a competitor to Genzyme s drug for Gaucher disease and disclosing that US regulators will let doctors prescribe the rival drug before it is approved for commercial use. Supplies of Genzyme s enzyme replacement therapy Cerezyme, currently the only drug on the market to treat the rare genetic disorder, were interrupted in June when a virus was detected in the... (Boston Globe)
Hagens Berman Investigating Potential Securities Violations At Genzyme Corporation On Behalf of Investors Aug 4, 2009
SEATTLE, Aug. 3, 2009 (GLOBE NEWSWIRE) -- Hagens Berman Sobol Shapiro is investigating reports of possible securities law violations by Genzyme Corporation (Nasdaq: - ), a biotechnology company, following reports that the company may have delayed news concerning manufacturing problems and plant inspections by the Food and Drug Administration (FDA). Published reports claim Genzyme did not share operational problems the company experienced in two of its plants, creating a shortage of its drug... (Primezone Releases)
Lack of treatment options boosts drug Aug 4, 2009
plc is reporting that the will allow the company to distribute its treatment for Gaucher disease before FDA approval, to blunt the effect of a shortage of the only drug on the market, Genzyme s Cerezyme ... Genzyme s production cannot currently meet projected demand following a temporary closure at the company s manufacturing facility in Allston, due to contamination by a virus ... Genzyme has resumed production of the medicine but it takes four months to develop from start to finish. (Philadelphia Business Journal, PA)
Get to know that amorphous Lewin Group Aug 2, 2009
(Page A1) quotes CEOs of Tufts Medical Center, Partners HealthCare, Beth Israel Deaconess Medical Center, Caritas Christi Health Care, Blue Cross and Blue Shield of Massachusetts, Tufts Health Plan, Boston Scientific, and Genzyme. (Page A4), an Associated Press story, makes reference to the Lewin Group, identified only as a private health research firm. (Boston Globe -- Editorial)
FDA to Genzyme: plant not OK Aug 2, 2009
Genzyme s stock (Nasdaq: GENZ) slid 6 ... During the re-inspection, the FDA will also review Genzyme s decontamination efforts following the June 16 shutdown of the plant due to the discovery of the virus in one of the bioreactors ... Genzyme officials have said that the virus that caused the shutdown was unrelated to the maintenance issues detailed in the FDA s warning letter. (Boston Business Journal, MA)
Indexes End Week, Month With Gains Aug 2, 2009
eIBD Investor's Business Daily Digital Edition. Access recent eIBD issues easily. (Investors Business Daily)
Genzyme sues firm over drug patent Aug 1, 2009
Genzyme, based in Cambridge, Mass ... Genzyme asks a judge to award unspecified damages if Roxane engages in the commercial manufacture, use, offer to sell, or sale of the capsules in the United States in violation of the patent ... Hectorol sales rose 11 percent in 2008 to $128 million, according to Genzyme, which reported $4. (Boston Globe)
Genzyme says FDA will reinspect Allston plant Aug 1, 2009
Shares of Cambridge-based Genzyme tumbled 7 ... Genzyme this week resumed production in Allston of a pair of biotech drugs for rare genetic disorders ... Genzyme spokesman Bo Piela said the new FDA visit, which has yet to be scheduled, will address two separate but related issues. (Boston Globe)
Suit blames Genzyme for stock losses Jul 30, 2009
Genzyme shares sank 8 ... Genzyme s misrepresentations caused investors to lose more than $8 billion since August of last year, shareholder Jon Rahn said in a complaint filed yesterday in federal court in Boston ... Genzyme said in June that it would ration two drugs, Cerezyme and Fabrazyme, after shutting its Allston Landing plant in Boston. (Boston Globe)
Ranbaxy to shift admin to Mumbai Jul 30, 2009
This is a good opportunity for other Delhi-based pharma companies such as Merck MSD, Jubilant Organosys, Genzyme and Panacea Biotec to tap Ranbaxy employees who may not want to relocate to Mumbai, a person close to the matter said, requesting not to be identified. Read business stories in. (India Times)
Gardy & Notis, LLP Files Securities Fraud Class Action Against Genzyme Corporation -- GENZ Jul 30, 2009
Gardy & Notis, LLP Files Securities Fraud Class Action Against Genzyme Corporation -- GENZ - Yahoo ... Gardy & Notis, LLP Files Securities Fraud Class Action Against Genzyme Corporation -- GENZ ... ENGLEWOOD CLIFFS, N.J., July 29, 2009 (GLOBE NEWSWIRE) -- Gardy & Notis, LLP has filed a securities fraud class action lawsuit on behalf of all investors who purchased or otherwise acquired Genzyme Corporation ("Genzyme") (Nasdaq: - ) common stock between June 26, 2008 and July 21, 2009 (the "Class... (Primezone Releases)
Setting Boston up for the future Jul 29, 2009
They came from companies across the region - from John Hancock, State Street, PricewaterhouseCoopers, Genzyme, Blue Cross Blue Shield of Massachusetts, and nearly 50 more - and they came to hear about Boston. What makes our city special. (Boston Globe)
Fresh Meats Often Contain Additives Harmful To Kidney Disease Patients Jul 25, 2009
The study was funded by grants from Genzyme, Inc. and Dialysis Clinics, Inc.. Journal reference. (Science Daily)
Genzyme's profit more than doubles Jul 23, 2009
A worker scrubbed pipes at Genzyme s Allston facility last month ... Genzyme Corp. s second-quarter profit more than doubled, mainly on lower charges and research and development expenses, but the Cambridge company slashed its outlook because of production issues ... More recently, Genzyme had to shut down and decontaminate a facility in Allston that makes the genetic disorder treatments Fabrazyme and Cerezyme. (Boston Globe)
